Argenx's Vyvgart Surges Past Sales Forecasts, Fueling Optimism for Autoimmune Portfolio
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.